London, UK – Royal Philips Electronics (NYSE: PHG, AEX: PHI) UK introduces its latest advancements in airway secretion management, an effective, gentle alternative to traditional suctioning methods, for adult and paediatric patients who are unable to cough or clear secretions effectively. The new CoughAssist E70 is a comprehensive solution with advanced therapy features and tools to help physicians smoothly transition their patients from hospital to home, offering more freedom and support.
With many diseases, a weakened ability to cough and remove secretions increases the chance of infection. The use of CoughAssist has been shown to significantly reduce hospitalization rates for respiratory complications of neuromuscular disease1. CoughAssist is a mechanical in-exsufflation device which clears secretions from the lungs by simulating a natural cough, gradually applying positive pressure to the airway and then rapidly shifting to negative pressure. Air is delivered through a facemask, a mouthpiece, or through a simple adapter to tracheostomy or an endotracheal tube.
Philips Respironics is a leader in helping to improve comfort and quality of life for patients with respiratory failures through advanced therapy. “We are committed to working with physicians and the entire care team as allies for better patient care,” said Erik Hollander, Global Head of Marketing, Philips Home Healthcare Solutions. “We have solutions that support every step of the patient care pathway: titration, discharge, home therapy, and follow-up. We provide technology, tools, accessories and software to integrate treatment into patients’ daily lives and help reduce the risk of hospital readmissions.”
The new features of the CoughAssist E70 may help to improve airway secretion removal by giving patients more control of their therapy. The Cough-Trak algorithm triggers a full cough upon every inspiration. Additionally, adjustable oscillation levels help in releasing mucus from the bronchial walls by applying vibrations to the airway.
To enhance patient mobility, the device is lightweight (weighs less than 4kg) and is compatible with an integrated detachable battery. An intuitive user interface with preset prescriptions simplifies setup and initiating therapy. New monitoring and data management tools allow for close follow-up at home, so that clinicians can assess therapy efficacy and adapt settings accordingly.
These new advancements are designed to support clinicians to optimize therapy and enhance patient comfort, mobility and compliance. The CoughAssist E70 is not available in the USA. For more information, visit: www.philips.com/coughassistE70.
1. CoughAssist therapy proven to reduce recurrent respiratory infections.
Alice C. Tzeng and John R. Bach. Prevention of Pulmonary Morbidity or Patients with Neuromuscular Disease. Chest 2000;118: 1390-1396. DOI 10. 1378/chest 118.5.1390.